Patents by Inventor Chadwick T. King
Chadwick T. King has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965029Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: GrantFiled: June 4, 2021Date of Patent: April 23, 2024Assignee: Amgen Inc.Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
-
Patent number: 11897965Abstract: Methods of treating conditions related to lung disease using an antigen binding protein specific for the Jagged1 polypeptide are provided.Type: GrantFiled: February 16, 2022Date of Patent: February 13, 2024Assignee: AMGEN INC.Inventors: Brian D. Bennett, Chadwick T. King, Jonathan Phillips
-
Patent number: 11897963Abstract: Methods of treating conditions related to lung disease using an antigen binding protein specific for the Jagged1 polypeptide are provided.Type: GrantFiled: May 13, 2021Date of Patent: February 13, 2024Assignee: AMGEN INC.Inventors: Brian D. Bennett, Chadwick T. King, Jonathan Phillips
-
Publication number: 20220169744Abstract: Methods of treating conditions related to lung disease using an antigen binding protein specific for the Jagged1 polypeptide are provided.Type: ApplicationFiled: February 16, 2022Publication date: June 2, 2022Inventors: Brian D. BENNETT, Chadwick T. KING, Jonathan PHILLIPS
-
Publication number: 20220119537Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: ApplicationFiled: June 4, 2021Publication date: April 21, 2022Applicant: Amgen Inc.Inventors: Dirk E. SMITH, Ian FOLTZ, Chadwick T. KING, Ai Ching LIM, Rutilio CLARK, Michael R. COMEAU, Randal R. KETCHEM, Donghui SHI, Xiaoshan MIN, Zhulun WANG
-
Publication number: 20220056144Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.Type: ApplicationFiled: September 3, 2021Publication date: February 24, 2022Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
-
Publication number: 20210340270Abstract: Methods of treating conditions related to lung disease using an antigen binding protein specific for the Jagged1 polypeptide are provided.Type: ApplicationFiled: May 13, 2021Publication date: November 4, 2021Inventors: Brian D. BENNETT, Chadwick T. KING, Jonathan PHILLIPS
-
Patent number: 11059895Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: GrantFiled: January 8, 2019Date of Patent: July 13, 2021Assignee: Amgen Inc.Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
-
Publication number: 20210179723Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.Type: ApplicationFiled: December 3, 2020Publication date: June 17, 2021Applicant: AMGEN INC.Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, Jr., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
-
Publication number: 20210179722Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.Type: ApplicationFiled: December 3, 2020Publication date: June 17, 2021Applicant: AMGEN INC.Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, JR., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
-
Patent number: 11028180Abstract: Methods of treating conditions related to lung disease using an antigen binding protein specific for the Jagged1 polypeptide are provided.Type: GrantFiled: May 30, 2018Date of Patent: June 8, 2021Assignee: AMGEN INC.Inventors: Brian D. Bennett, Chadwick T. King, Jonathan Phillips
-
Publication number: 20190359724Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.Type: ApplicationFiled: August 7, 2019Publication date: November 28, 2019Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
-
Publication number: 20190359720Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: ApplicationFiled: January 8, 2019Publication date: November 28, 2019Applicant: Amgen Inc.Inventors: Dirk E. SMITH, Ian FOLTZ, Chadwick T. KING, Ai Ching LIM, Rutilio CLARK, Michael R. COMEAU, Randal R. KETCHEM, Donghui SHI, Xiaoshan MIN, Zhulun WANG
-
Patent number: 10421813Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.Type: GrantFiled: July 11, 2017Date of Patent: September 24, 2019Assignee: Kiniksa Pharmaceuticals, Ltd.Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
-
Patent number: 10227414Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: GrantFiled: May 22, 2017Date of Patent: March 12, 2019Assignee: Amgen Inc.Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
-
Publication number: 20190023802Abstract: Methods of treating conditions related to lung disease using an antigen binding protein specific for the Jagged1 polypeptide are provided.Type: ApplicationFiled: May 30, 2018Publication date: January 24, 2019Applicant: AMGEN INC.Inventors: Brian D. Bennett, Chadwick T. King, Jonathan Phillips
-
Patent number: 10118968Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: December 29, 2009Date of Patent: November 6, 2018Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 9982054Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: GrantFiled: June 10, 2016Date of Patent: May 29, 2018Assignee: AMGEN INC.Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
-
Publication number: 20180142029Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.Type: ApplicationFiled: November 28, 2017Publication date: May 24, 2018Applicant: AMGEN INC.Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, JR., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
-
Patent number: 9862771Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.Type: GrantFiled: June 26, 2015Date of Patent: January 9, 2018Assignee: AMGEN INC.Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, Jr., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu